Dimethyl Fumarate — Membership Pricing

Other medications in Neurological

• Donepezil
• Edaravone
• Entacapone
• Eptinezumab
• Erenumab
• Eslicarbazepine
• Felbamate
• Fenfluramine

About Dimethyl Fumarate

Dimethyl fumarate is a widely prescribed oral medication for managing multiple sclerosis, helping patients live fuller lives. Understanding this treatment is key, and at TheDrugClub, we're dedicated to helping our members access significant savings on vital prescriptions like dimethyl fumarate, ensuring care is more accessible and affordable for you.

The information above is for educational purposes only and does not constitute medical advice. Consult your healthcare provider before making medication decisions.

What Dimethyl Fumarate is approved for (FDA label)

Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. Dimethyl fumarate delayed-release capsules are indicated for the treatment of relapsing forms of multiple sclerosis (MS), to include clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease, in adults. ( 1 )

Source: Read the full FDA label on DailyMed. Label effective date: June 3, 2026.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Dosage forms and strengths for Dimethyl Fumarate (FDA label)

Dimethyl fumarate is available as hard gelatin delayed-release capsules containing 120 mg or 240 mg of dimethyl fumarate. Dimethyl fumarate delayed-release capsules, 120 mg are white cap/white body size ‘0’ hard gelatin capsules imprinted in black ink with “DMT 120” on the body containing white to off-white, round shaped biconvex tablets, plain on both sides. Dimethyl fumarate delayed-release capsules, 240 mg are green cap/green body size ‘0’ hard gelatin capsules imprinted in black ink with “DMT 240” on the body containing white to off-white, round shaped biconvex tablets, plain on both sides. Delayed-release capsules : 120 mg and 240 mg ( 3 )

Source: FDA prescribing information (DailyMed). Set ID: 5361d5c6-c3eb-88e6-e063-6294a90ac08c. SPL document ID: 5361d4c3-ed4f-9afd-e063-6294a90a42ec. Label effective date: June 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Adverse reactions for Dimethyl Fumarate (FDA label)

The following important adverse reactions are described elsewhere in labeling: Anaphylaxis and Angioedema [see Warnings and Precautions (5.1) ] Progressive multifocal leukoencephalopathy [see Warnings and Precautions (5.2) ] Herpes Zoster and Other Serious Opportunistic Infections [see Warnings and Precautions (5.3) ] Lymphopenia [see Warnings and Precautions (5.4) ] Liver Injury [see Warnings and Precautions (5.5) ] Flushing [see Warnings and Precautions (5.6) ] Serious Gastrointestinal Reactions [see Warnings and Precautions (5.7) ] Most common adverse reactions (incidence ≥10% and ≥2% placebo) were flushing, abdominal pain, diarrhea, and nausea. ( 6.1 ) To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch. 6.1 Clinical Trials Experience Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in clinical practice.

Source: FDA prescribing information (DailyMed). Set ID: 5361d5c6-c3eb-88e6-e063-6294a90ac08c. SPL document ID: 5361d4c3-ed4f-9afd-e063-6294a90a42ec. Label effective date: June 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Contraindications for Dimethyl Fumarate (FDA label)

Dimethyl fumarate delayed-release capsules are contraindicated in patients with known hypersensitivity to dimethyl fumarate or to any of the excipients of dimethyl fumarate delayed-release capsules. Reactions have included anaphylaxis and angioedema [see Warnings and Precautions (5.1) ]. Known hypersensitivity to dimethyl fumarate or any of the excipients of dimethyl fumarate delayed-release capsules. ( 4 )

Source: FDA prescribing information (DailyMed). Set ID: 5361d5c6-c3eb-88e6-e063-6294a90ac08c. SPL document ID: 5361d4c3-ed4f-9afd-e063-6294a90a42ec. Label effective date: June 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.

Warnings and precautions for Dimethyl Fumarate (FDA label)

Anaphylaxis and Angioedema: Discontinue and do not restart dimethyl fumarate delayed-release capsules if these occur. ( 5.1 ) Progressive Multifocal Leukoencephalopathy (PML): Withhold dimethyl fumarate delayed-release capsules at the first sign or symptom suggestive of PML. ( 5.2 ) Herpes Zoster and Other Serious Opportunistic Infections: Consider withholding dimethyl fumarate delayed-release capsules in cases of serious infection until the infection has resolved. ( 5.3 ) Lymphopenia: Obtain a CBC including lymphocyte count before initiating dimethyl fumarate delayed-release capsules, after 6 months, and every 6 to 12 months thereafter. Consider interruption of dimethyl fumarate delayed-release capsules if lymphocyte counts <0.5 x 10 9 /L persist for more than 6 months. ( 5.4 ) Liver Injury: Obtain serum aminotransferase, alkaline phosphatase, and total bilirubin levels before initiating dimethyl fumarate delayed-release capsules and during treatment, as clinically indicated.

Source: FDA prescribing information (DailyMed). Set ID: 5361d5c6-c3eb-88e6-e063-6294a90ac08c. SPL document ID: 5361d4c3-ed4f-9afd-e063-6294a90a42ec. Label effective date: June 3, 2026. Read the full label.

Excerpt from the FDA-approved prescribing information. This is not medical advice; talk to your doctor or pharmacist.